Dante Genomics, a global leader in genomics and precision medicine, announced today the formal commencement of ColoAlert’s consumer commercial program in Italy and the United Arab Emirates (UAE).
Dante Genomics, a global leader in genomics and precision medicine, today announced that members of its management team will participate in the Canaccord Genuity 42nd Annual Growth Conference, and Andrea Riposati, CEO of Dante Genomics, will participate in a panel presentation on leveraging omics-based data and analytics to advance precision health to the next level on Thursday, August 11, 2022 at 9:30 AM Eastern Time.
Dante Genomics is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes from diagnostics to therapeutics with assets including one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.
Dante Labs, a global leader in genomics and precision medicine, today announced the launch of Dante Genomics, an online marketplace portal specifically dedicated to healthcare providers, clinics, researchers and governments which will offer advanced genomic services for research and clinical applications.
Dante Labs, a global leader in genomics and precision medicine, is pleased to announce that on January 19, 2022, the Dante Labs Sequencing Center in Dubai was issued a license as a authorized medical laboratory for genomics.
